Estrogen Receptor Positive (ER+) Breast Cancer Outlook 2017 Industry Estrogen Receptor Positive (ER+) Breast Cancer | Page 3

Estrogen Receptor Positive (ER+) Breast Cancer -
Treatment Landscape & Competitive Analysis,
2017
This report provides the insights of the marketed drugs for the Estrogen Receptor Positive (ER+) Breast
Cancer which includes the Targeted Therapy, Hormone Therapy and Chemotherapy. In case of Estrogen
Receptor Positive (ER+) Breast Cancer, Hormone therapy is the main focus of treatment after surgery and
chemotherapy. Hormonal therapy is usually recommended after 5 years of surgery and can be divided into
Estrogen blocking hormonal therapy and estrogen lowering hormonal therapy based on the mechanism of
action of the hormonal therapy drugs. Of all the late-stage pipeline drugs, Buparlisib is expected to reach the
market in the next few years.
This report covers the treatment landscape which provides the treatment options by different stages and
type of the breast cancer. There are four chemotherapy drugs, six hormone therapy drugs and one targeted
therapy drugs in market for the treatment of Estrogen Receptor Positive (ER+) Breast Cancer.
Key Report Highlights on Estrogen Receptor Positive (ER+) Breast Cancer Industry:
The new report, provides a Estrogen Receptor Positive (ER+) Breast Cancer Treatment Landscape across the
globe. The report provides profiles of the marketed drug which includes the product description, cost of
treatment, development partner, patent expiry date, sales data etc.
Inquire more before buying this report at
http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=894781.